Market News
- FDA’s Oncologic Drugs Advisory Committee Recommends Earlier Treatment with Carvykti for Relapsed or Refractory Multiple Myelomaby OncLive articles on March 18, 2024
In a unanimous decision, the committee recommended Carvykti based on promising data from the Phase III CARTITUDE-4 study, which showed a positive risk-benefit assessment.
- Adalimumab biosimilar by Biocon for Plaque Psoriasis (Psoriasis Vulgaris): Likelihood of Approvalby kgi-admin (Pharmaceutical Technology) on March 18, 2024
Adalimumab biosimilar is under clinical development by Biocon and currently in Phase III for Plaque Psoriasis (Psoriasis Vulgaris).
- Tempol by DMK Pharmaceuticals for Radiodermatitis: Likelihood of Approvalby kgi-admin (Pharmaceutical Technology) on March 18, 2024
Tempol is under clinical development by DMK Pharmaceuticals and currently in Phase II for Radiodermatitis.
- Defining the HTA landscape for France and Germany: 2019–2023by Alex Watt (Pharmaceutical Technology) on March 18, 2024
Using GlobalData’s POLI & HTA database, analysis has been conducted that will provide insight into how the HTA landscape adapted between 2019 and 2023.
- Bluebird, short on cash, takes on $175M in debt financingby Delilah Alvarado (BioPharma Dive – Latest News) on March 18, 2024
The funding could extend the cash-strapped gene therapy maker’s financial runway to 2026, but only if the company successfully hits certain milestones.
- Despite inquiry, FDA AdCom backs BMS Abecma approvalby Phalguni Deswal (Pharmaceutical Technology) on March 18, 2024
AdCom voted eight to three in favour of BMS and 2seventy bio’s CAR-T cell therapy, Abecma in triple-class exposed multiple myeloma patients.
- AI’s Impact on CEO/Founder Sustainabilityby OncLive articles on March 18, 2024
In this Pharmaceutical Executive video interview, Kaveh Vahdat, Founder and President of RiseOpp, discusses the impact AI will have on thelong-term well-being of founders and CEOs.
- Empowering clinical trials: The technological revolution in patient retentionby Alexander Love (Pharmaceutical Technology) on March 18, 2024
In the realm of clinical trials, participant retention is a cornerstone for success, offering robustness to the data collected and ensuring the validity of the trial outcomes.
- Norgine secures Pedmarqsi licence from Fennec in deal worth up to $272mby Robert Barrie (Pharmaceutical Technology) on March 18, 2024
Fennec’s Pedmarqsi/Pedmark is the only approved therapy to treat cisplatin-induced hearing loss in paediatric cancer patients.
- Pharma Pulse 3/18/24: Alcohol Use Disorder Equally Linked to Suicide Across Genders, Can Personal Medical Devices Be Recycled? & moreby OncLive articles on March 18, 2024
The latest news for pharma industry insiders.
- Precision Medicine: Investments and Outcomes Expectedby OncLive articles on March 18, 2024
Precision medicine is now seen as a healthcare approach for both the present and the future, particularly with the explosion of personalized care delivery.
- Novartis begins expansion of Singapore biopharmaceutical plantby Archana Rani (Pharmaceutical Technology) on March 18, 2024
Novartis has broken ground on the expansion of its $256m biopharmaceutical manufacturing facility in Singapore.
- Akums introduces Hydroxyurea oral suspension for sickle cell diseaseby Vishnu Priyan (Pharmaceutical Technology) on March 18, 2024
Akums Drugs and Pharmaceuticals has introduced Hydroxyurea oral suspension, a room temperature-stable drug for treating sickle cell disease.
- New Report Shows AI Improved Treatments for Biofilm Infectionsby OncLive articles on March 18, 2024
The technology was used to develop new peptides.
- Study Compares Differences in Antibiotic Prescribing for Pediatric Acute Respiratory Tract Infection Between Primary Care Telemedicine, Virtual-Only DTC Telemedicine Appointmentsby OncLive articles on March 18, 2024
Investigation aimed to discern whether the differences in antibiotic prescribing between direct-to-consumer telemedicine appointments and primary care physician telemedicine appointments were due to the care modality or the context of the care.
- Deadly Brain Tumors May Be Treatable with New CAR-T Therapy, Study Suggestsby OncLive articles on March 18, 2024
The therapies are still in the early stages of development, but researchers are optimistic about the results.
- The digital divide: Balancing automation and human interaction regardless of the patient support program modelby BioPharma Dive – Latest News on March 18, 2024
Balancing automated patient support with human touch is key in healthcare. Hybrid models offer a pragmatic path forward, prioritizing patient-centricity.
- Give HCPs a proactive way to reach your field team: Add inboundby Paul Shawah, Executive Vice President of Strategy, Veeva (BioPharma Dive – Latest News) on March 18, 2024
HCPs today want inbound channels for help when they need it. See how you can meet their preferences.
- Optinose’s XHANCE nasal spray gains approval for chronic sinusitisby Vishnu Priyan (Pharmaceutical Technology) on March 18, 2024
The US FDA has granted approval for Optinose’s XHANCE nasal spray for chronic rhinosinusitis without nasal polyps in adult patients.
- FDA committee endorses Johnson & Johnson’s multiple myeloma therapyby Vishnu Priyan (Pharmaceutical Technology) on March 18, 2024
The US FDA’s ODAC has recommended Johnson & Johnson’s CARVYKTI to treat relapsed or refractory multiple myeloma (R/R MM).